Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.

Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, Ahlman MA, Stetler-Stevenson M, Yuan C, Guo S, Liu S, Hughes SH, Fry TJ, Wu X.

Blood Adv. 2019 Aug 13;3(15):2317-2322. doi: 10.1182/bloodadvances.2019000219. No abstract available.

2.

Introduction: Immunological Reviews volume 290.

Fry TJ.

Immunol Rev. 2019 Jul;290(1):4-5. doi: 10.1111/imr.12797. No abstract available.

PMID:
31355490
3.

Multi-Specific CAR Targeting to Prevent Antigen Escape.

Walsh Z, Ross S, Fry TJ.

Curr Hematol Malig Rep. 2019 Jul 22. doi: 10.1007/s11899-019-00537-5. [Epub ahead of print] Review.

PMID:
31332617
4.

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer JN, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF.

Mol Ther. 2019 Jul 3;27(7):1275-1285. doi: 10.1016/j.ymthe.2019.05.015. Epub 2019 May 30.

PMID:
31178392
5.

Introduction by the Guest Editor, Terry J. Fry.

Fry TJ.

Cancer J. 2019 May/Jun;25(3):178. doi: 10.1097/PPO.0000000000000382. No abstract available.

PMID:
31135524
6.

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, Qin H, Kraft IL, Stetler-Stevenson M, Yuan CM, Hwang JD, Feng Y, Zhu Z, Dimitrov D, Shah NN, Fry TJ.

Clin Cancer Res. 2019 Sep 1;25(17):5329-5341. doi: 10.1158/1078-0432.CCR-18-3784. Epub 2019 May 20.

PMID:
31110075
7.

Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.

Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW.

Mol Ther. 2019 Jul 3;27(7):1262-1274. doi: 10.1016/j.ymthe.2019.04.010. Epub 2019 Apr 17.

PMID:
31043341
8.

Mechanisms of resistance to CAR T cell therapy.

Shah NN, Fry TJ.

Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6. Review.

PMID:
30837712
9.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.

J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.

10.

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.

Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, Yuan CM, Haso W, Shern JF, Shah NN, Fry TJ.

Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.

11.

Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.

Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):577-586. doi: 10.1016/j.bbmt.2018.10.011. Epub 2018 Oct 18.

PMID:
30342913
12.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

13.

Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor.

Qin H, Ishii K, Nguyen S, Su PP, Burk CR, Kim BH, Duncan BB, Tarun S, Shah NN, Kohler ME, Fry TJ.

Blood. 2018 Nov 1;132(18):1899-1910. doi: 10.1182/blood-2017-12-815548. Epub 2018 Sep 12.

PMID:
30209120
14.

Chimeric Antigen Receptor T-Cell Therapy.

Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST.

J Natl Compr Canc Netw. 2018 Sep;16(9):1092-1106. doi: 10.6004/jnccn.2018.0073.

PMID:
30181421
15.

Systematic Review of Quality Improvement Initiatives Related to Cue-Based Feeding in Preterm Infants.

Fry TJ, Marfurt S, Wengier S.

Nurs Womens Health. 2018 Oct;22(5):401-410. doi: 10.1016/j.nwh.2018.07.006. Epub 2018 Aug 21. Review.

PMID:
30138603
16.

Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.

Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Struemph K, Kane E, Yates B, Delbrook C, Mackall CL, Lee DW, Fry TJ, Shah NN.

J Immunother. 2018 Sep;41(7):350-358. doi: 10.1097/CJI.0000000000000241.

17.

Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2040-2046. doi: 10.1016/j.bbmt.2018.06.010. Epub 2018 Jun 19.

PMID:
29933069
18.

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.

Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES, Lee DW, Shern JF, Fry TJ, Shah NN.

Haematologica. 2018 May;103(5):e215-e218. doi: 10.3324/haematol.2017.183459. Epub 2018 Feb 1. No abstract available.

19.

Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways.

Gough SM, Goldberg L, Pineda M, Walker RL, Zhu YJ, Bilke S, Chung YJ, Dufraine J, Kundu S, Jacoby E, Fry TJ, Fischer S, Panzer-Grümayer R, Meltzer PS, Aplan PD.

Blood Adv. 2017 Sep 8;1(20):1749-1759. doi: 10.1182/bloodadvances.2017009837. eCollection 2017 Sep 12.

20.

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance.

Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C, Hu Y, Wanhainen K, Qin H, Fry TJ.

Sci Transl Med. 2017 Nov 22;9(417). pii: eaag1209. doi: 10.1126/scitranslmed.aag1209.

PMID:
29167392
21.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

22.

Anti-CD19 resistance can "stem" from progenitors.

Shah NN, Fry TJ.

Blood. 2017 Nov 2;130(18):1961-1963. doi: 10.1182/blood-2017-09-804070. No abstract available.

23.

Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.

Chung YJ, Fry TJ, Aplan PD.

PLoS One. 2017 Sep 27;12(9):e0185219. doi: 10.1371/journal.pone.0185219. eCollection 2017.

24.

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL.

Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.

25.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.

Stroncek DF, Lee DW, Ren J, Sabatino M, Highfill S, Khuu H, Shah NN, Kaplan RN, Fry TJ, Mackall CL.

J Transl Med. 2017 Mar 16;15(1):59. doi: 10.1186/s12967-017-1160-5.

26.

Autologous lymphapheresis for the production of chimeric antigen receptor T cells.

Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, Lee DW, Mackall CL, Conry-Cantilena C.

Transfusion. 2017 May;57(5):1133-1141. doi: 10.1111/trf.14003. Epub 2017 Feb 24.

27.

Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation.

Shah NN, Watson TM, Yates B, Liewehr DJ, Steinberg SM, Jacobsohn D, Fry TJ.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26273. Epub 2016 Oct 20.

PMID:
27762068
28.

Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2149-2154. doi: 10.1016/j.bbmt.2016.08.028. Epub 2016 Sep 12.

29.

The functional interplay between systemic cancer and the hematopoietic stem cell niche.

Giles AJ, Chien CD, Reid CM, Fry TJ, Park DM, Kaplan RN, Gilbert MR.

Pharmacol Ther. 2016 Dec;168:53-60. doi: 10.1016/j.pharmthera.2016.09.006. Epub 2016 Sep 2. Review.

30.

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ.

Nat Commun. 2016 Jul 27;7:12320. doi: 10.1038/ncomms12320.

31.

Extinct Beringian wolf morphotype found in the continental U.S. has implications for wolf migration and evolution.

Meachen JA, Brannick AL, Fry TJ.

Ecol Evol. 2016 Apr 24;6(10):3430-8. doi: 10.1002/ece3.2141. eCollection 2016 May.

32.

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, Gress RE, Kochenderfer JN, Stroncek DF, Ji Y, Gattinoni L.

Blood. 2016 Jul 28;128(4):519-28. doi: 10.1182/blood-2015-11-683847. Epub 2016 May 25.

33.

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ.

Blood. 2016 Mar 10;127(10):1361-70. doi: 10.1182/blood-2015-08-664250. Epub 2015 Dec 11.

34.

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

Shalabi H, Angiolillo A, Fry TJ.

Front Pediatr. 2015 Oct 1;3:80. doi: 10.3389/fped.2015.00080. eCollection 2015. Review.

35.

Challenges and opportunities of allogeneic donor-derived CAR T cells.

Yang Y, Jacoby E, Fry TJ.

Curr Opin Hematol. 2015 Nov;22(6):509-515. doi: 10.1097/MOH.0000000000000181. Review.

36.

A robust in vivo model for B cell precursor acute lymphoblastic leukemia.

Fry TJ, Aplan PD.

J Clin Invest. 2015 Sep;125(9):3427-9. doi: 10.1172/JCI83799. Epub 2015 Aug 24. Review.

37.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ.

Blood. 2015 Jul 30;126(5):629-39. doi: 10.1182/blood-2014-11-612903. Epub 2015 Jun 3. Erratum in: Blood. 2016 Sep 8;128(10):1441.

38.

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL.

Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.

39.

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL.

Blood. 2015 Jan 29;125(5):784-92. doi: 10.1182/blood-2014-07-592881. Epub 2014 Dec 1.

40.

Immune-based therapies for childhood cancer.

Mackall CL, Merchant MS, Fry TJ.

Nat Rev Clin Oncol. 2014 Dec;11(12):693-703. doi: 10.1038/nrclinonc.2014.177. Epub 2014 Oct 28. Review.

PMID:
25348789
41.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
42.

Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.

Capitini CM, Nasholm NM, Chien CD, Larabee SM, Qin H, Song YK, Klover PJ, Hennighausen L, Khan J, Fry TJ.

Blood. 2014 Sep 18;124(12):1976-86. doi: 10.1182/blood-2013-05-500876. Epub 2014 Jul 25.

43.

Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.

Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J.

Front Oncol. 2014 Jun 10;4:134. doi: 10.3389/fonc.2014.00134. eCollection 2014. Review.

44.

Murine models of acute leukemia: important tools in current pediatric leukemia research.

Jacoby E, Chien CD, Fry TJ.

Front Oncol. 2014 May 7;4:95. doi: 10.3389/fonc.2014.00095. eCollection 2014. Review.

45.

A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW.

Vaccine. 2014 May 30;32(26):3223-31. doi: 10.1016/j.vaccine.2014.04.008. Epub 2014 Apr 13.

46.

T-cell adoptive immunotherapy for acute lymphoblastic leukemia.

Fry TJ, Mackall CL.

Hematology Am Soc Hematol Educ Program. 2013;2013:348-53. doi: 10.1182/asheducation-2013.1.348. Review.

PMID:
24319203
47.

Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.

Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ.

Biol Blood Marrow Transplant. 2014 Jan;20(1):26-36. doi: 10.1016/j.bbmt.2013.10.009. Epub 2013 Oct 17.

48.

A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ.

J Immunother. 2013 Oct;36(8):400-11. doi: 10.1097/CJI.0b013e3182a80213.

49.

Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.

Walsh MP, Duncan B, Larabee S, Krauss A, Davis JP, Cui Y, Kim SY, Guimond M, Bachovchin W, Fry TJ.

PLoS One. 2013;8(3):e58860. doi: 10.1371/journal.pone.0058860. Epub 2013 Mar 12.

50.

Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.

Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ.

J Immunol. 2013 Feb 1;190(3):1351-9. doi: 10.4049/jimmunol.1200391. Epub 2012 Dec 28.

Supplemental Content

Support Center